HER2検査市場レポート：2030年までの動向、予測、競合分析

HER2検査の動向と予測

世界のHER2検査市場は、2024年から2030年にかけてCAGR 7.1％で成長すると予測されます。この市場の主な促進要因は、個別化医療アプローチの重要性の高まりと、乳がんおよび胃がんの有病率の急増です。世界のHER2検査市場の将来は、病院と診断ラボ市場における機会によって有望視されています。

セグメント別HER2検査

この調査には、世界のHER2検査の技術別、がんの種類別、最終用途別、地域別の予測が含まれています。

HER2検査市場の洞察

Lucintel社は、蛍光in situハイブリダイゼーション (FISH) は、費用対効果と迅速な納期により、予測期間中最大のセグメントであり続けると予測しています。

この市場では、専門的な医療機器やインフラが利用可能であることから、病院が最大のセグメントであり続けると思われます。

北米は乳がんの有病率が高いため、予測期間中も最大の地域であり続けると思われます。

よくある質問

Q1.市場の成長予測は：

A1.世界のHER2検査市場は、2024年から2030年にかけてCAGR 7.1％で成長する見込みです。

Q2.市場の成長に影響を与える主な促進要因は：

A2.この市場の主な促進要因は、個別化医療アプローチの重要性の高まりと、乳がんおよび胃がんの有病率の急増です。

Q3.市場の主要セグメントは：

A3.HER2検査市場の将来は、病院および診断ラボ市場での機会により有望と思われます。

Q4.市場の主要企業は：

A4.HER2検査の主要企業は以下の通りである：

• Abbott
• Hoffmann-La Roche
• Agilent Technologies
• Thermo Fisher Scientific
• Leica Biosystems
• Empire Genomics
• Bio-Genex Laboratories

Q5.今後、最大となる市場セグメントは：

A5.Lucintelは、蛍光in situハイブリダイゼーション (FISH) は費用対効果が高く、納期が早いため、予測期間中も最大セグメントであり続けると予測しています。

Q6.市場において、今後5年間に最大になると予想される地域は：

A6.北米は乳がんの有病率が高いため、予測期間中も最大の地域です。

Q7.レポートのカスタマイズは可能か：

A7.はい、Lucintelは追加費用なしで10％のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界のHER2検査市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

• マクロ経済動向（2018～2023年）と予測（2024～2030年）
• 世界のHER2検査市場の動向（2018-2023）と予測（2024-2030）
• 技術別HER2検査の世界市場
  • 蛍光in situハイブリダイゼーション (FISH)
  • デュアルプローブ
  • シングルプローブ
  • 発色in situハイブリダイゼーション (CISH)
  • 銀増感in situハイブリダイゼーション
• がん種別のHER2検査の世界市場
  • 乳がん
  • 胃がん
• 最終用途別HER2検査の世界市場
  • 病院
  • 診断検査室
  • その他

第4章 2018年から2030年までの地域別市場動向と予測分析

• 地域別HER2検査市場
• 北米HER2検査市場
• 欧州のHER2検査市場
• アジア太平洋のHER2検査市場
• その他地域のHER2検査市場

第5章 競合分析

• 製品ポートフォリオ分析
• 業務統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • 技術別のHER2検査市場における成長機会
  • がんの種類別の世界HER2検査市場の成長機会
  • 最終用途別の世界のHER2検査市場の成長機会
  • 地域別の世界のHER2検査市場の成長機会
• 世界のHER2検査市場の新たな動向
• 戦略分析
  • 新製品の開発
  • 世界のHER2検査市場の能力拡大
  • 世界のHER2検査市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 主要企業の企業プロファイル

• Abbott
• Hoffmann-La Roche
• Agilent Technologies
• Thermo Fisher Scientific
• Leica Biosystems
• Empire Genomics
• Bio-Genex Laboratories

HER2 Testing Trends and Forecast

The future of the global HER2 testing market looks promising with opportunities in the hospitals and diagnostic laboratories markets. The global HER2 testing market is expected to grow with a CAGR of 7.1% from 2024 to 2030. The major drivers for this market are increasing significance of personalized medical approaches and surge in the prevalence of breast and gastric cancers.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

HER2 Testing by Segment

The study includes a forecast for the global HER2 testing by technique, cancer type, end use, and region.

HER2 Testing Market by Technique [Shipment Analysis by Value from 2018 to 2030]:

• Fluorescence In Situ Hybridization
• Dual-Probe
• Single-Probe
• Chromogenic In Situ Hybridization
• Silver-Enhanced In Situ Hybridization

HER2 Testing Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:

• Breast Cancer
• Gastric Cancer

HER2 Testing Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals
• Diagnostic Laboratories
• Others

HER2 Testing Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of HER2 Testing Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies HER2 testing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the HER2 testing companies profiled in this report include-

• Abbott
• Hoffmann-La Roche
• Agilent Technologies
• Thermo Fisher Scientific
• Leica Biosystems
• Empire Genomics
• Bio-Genex Laboratories

HER2 Testing Market Insights

Lucintel forecasts that fluorescence in situ hybridization will remain the largest segment over the forecast period due to their cost-effectiveness and faster turnaround times.

Within this market, hospitals will remain the largest segment due to availability of specialized medical equipment and infrastructure.

North America will remain the largest region over the forecast period due to high prevalence of breast cancer.

Features of the Global HER2 Testing Market

Market Size Estimates: HER2 testing market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: HER2 testing market size by technique, cancer type, end use, and region in terms of value ($B).

Regional Analysis: HER2 testing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different techniques, cancer types, end uses, and regions for the HER2 testing market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the HER2 testing market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for HER2 testing market?

Answer: The global HER2 testing market is expected to grow with a CAGR of 7.1% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the HER2 testing market?

Answer: The major drivers for this market are increasing significance of personalized medical approaches and surge in the prevalence of breast and gastric cancers.

Q3. What are the major segments for HER2 testing market?

Answer: The future of the HER2 testing market looks promising with opportunities in the hospitals and diagnostic laboratories markets.

Q4. Who are the key HER2 testing market companies?

Answer: Some of the key HER2 testing companies are as follows:

• Abbott
• Hoffmann-La Roche
• Agilent Technologies
• Thermo Fisher Scientific
• Leica Biosystems
• Empire Genomics
• Bio-Genex Laboratories

Q5. Which HER2 testing market segment will be the largest in future?

Answer: Lucintel forecasts that fluorescence in situ hybridization will remain the largest segment over the forecast period due to their cost-effectiveness and faster turnaround times.

Q6. In HER2 testing market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to high prevalence of breast cancer.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the HER2 testing market by technique (fluorescence in situ hybridization, dual-probe, single-probe, chromogenic in situ hybridization, and silver-enhanced in situ hybridization), cancer type (breast cancer and gastric cancer), end use (hospitals, diagnostic laboratories, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global HER2 Testing Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global HER2 Testing Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global HER2 Testing Market by Technique
  • 3.3.1: Fluorescence in situ hybridization
  • 3.3.2: Dual-probe
  • 3.3.3: Single-probe
  • 3.3.4: Chromogenic in situ hybridization
  • 3.3.5: Silver-enhanced in situ hybridization
• 3.4: Global HER2 Testing Market by Cancer Type
  • 3.4.1: Breast Cancer
  • 3.4.2: Gastric Cancer
• 3.5: Global HER2 Testing Market by End Use
  • 3.5.1: Hospitals
  • 3.5.2: Diagnostic Laboratories
  • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global HER2 Testing Market by Region
• 4.2: North American HER2 Testing Market
  • 4.2.1: North American HER2 Testing Market by Technique: Fluorescence in situ hybridization, Dual-probe, Single-probe, Chromogenic in situ hybridization, and Silver-enhanced in situ hybridization
  • 4.2.2: North American HER2 Testing Market by End Use: Hospitals, Diagnostic Laboratories, and Others
• 4.3: European HER2 Testing Market
  • 4.3.1: European HER2 Testing Market by Technique: Fluorescence in situ hybridization, Dual-probe, Single-probe, Chromogenic in situ hybridization, and Silver-enhanced in situ hybridization
  • 4.3.2: European HER2 Testing Market by End Use: Hospitals, Diagnostic Laboratories, and Others
• 4.4: APAC HER2 Testing Market
  • 4.4.1: APAC HER2 Testing Market by Technique: Fluorescence in situ hybridization, Dual-probe, Single-probe, Chromogenic in situ hybridization, and Silver-enhanced in situ hybridization
  • 4.4.2: APAC HER2 Testing Market by End Use: Hospitals, Diagnostic Laboratories, and Others
• 4.5: ROW HER2 Testing Market
  • 4.5.1: ROW HER2 Testing Market by Technique: Fluorescence in situ hybridization, Dual-probe, Single-probe, Chromogenic in situ hybridization, and Silver-enhanced in situ hybridization
  • 4.5.2: ROW HER2 Testing Market by End Use: Hospitals, Diagnostic Laboratories, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global HER2 Testing Market by Technique
  • 6.1.2: Growth Opportunities for the Global HER2 Testing Market by Cancer Type
  • 6.1.3: Growth Opportunities for the Global HER2 Testing Market by End Use
  • 6.1.4: Growth Opportunities for the Global HER2 Testing Market by Region
• 6.2: Emerging Trends in the Global HER2 Testing Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global HER2 Testing Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global HER2 Testing Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Abbott
• 7.2: Hoffmann-La Roche
• 7.3: Agilent Technologies
• 7.4: Thermo Fisher Scientific
• 7.5: Leica Biosystems
• 7.6: Empire Genomics
• 7.7: Bio-Genex Laboratories